Phio Pharmaceuticals (PHIO) vs Vistagen Therapeutics (VTGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Phio Pharmaceuticals (PHIO) has outperformed Vistagen Therapeutics (VTGN) over the past year, losing 41.4% versus a loss of 96.4%. Over five years, PHIO leads with a -99.6% price change compared with -99.7% for VTGN. Phio Pharmaceuticals is the larger company by market cap ($7.8 million vs $7.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHIO | VTGN |
|---|---|---|
| Share price | $0.656 | $0.1636 |
| Market cap | $7.84M | $7.56M |
| 1-day change | -8.25% | -12.33% |
| YTD return | -37.52% | -75.21% |
| 1-year return | -41.43% | -96.44% |
| 5-year return | -99.56% | -99.72% |
| EPS (TTM) | $-1.21 | $-1.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.27M |
| Revenue growth (YoY) | — | +161.11% |
| Net income (latest FY) | $-8.70M | $-69.69M |
| Operating margin | — | -5683.69% |
| Net margin | — | -5491.33% |
| 52-week high | $1.88 | $5.14 |
| 52-week low | $0.6395 | $0.16 |
| Distance from 52-week high | -65.11% | -96.82% |
| Analyst consensus | none | none |
| Avg. price target upside | +2034.15% | +511.25% |
| Average volume | 106.09K | 10.30M |
| Shares outstanding | 11.95M | 46.19M |
| Employees | 6 | 41 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHIO has outperformed VTGN by 55.0 percentage points over the past year.
About Phio Pharmaceuticals
PHIO stock →Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Vistagen Therapeutics
VTGN stock →Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
PHIO vs VTGN FAQ
Which is bigger, Phio Pharmaceuticals or Vistagen Therapeutics?
Phio Pharmaceuticals (PHIO) is larger, with a market capitalization of $7.84M compared with $7.56M for Vistagen Therapeutics (VTGN).
Which stock has performed better over the past year, PHIO or VTGN?
PHIO returned -41.43% over the past 12 months, compared with -96.44% for VTGN (price return, excluding dividends). Past performance does not predict future results.
Are Phio Pharmaceuticals and Vistagen Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.